Brendan J McMullan

Jul 2, 2024 | ep.bmj.com | Vivian Giang |Brendan J McMullan |UNSW Sydney

Cookies and privacyWe and our 87 partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data.Cookie policyUse precise geolocation data. Actively scan device characteristics for identification.

Apr 11, 2024 | medicalxpress.com | Archana Koirala |Brendan J McMullan |Emma Best |Fiona Russell

As we look towards the peak season for respiratory viruses, the announcement of new respiratory syncytial virus (RSV) immunization programs for children in a number of Australian states is welcome news. Last month Western Australia became the first Australian state or territory to announce a state government-funded immunization program against RSV. All babies under 8 months and those aged 8 to 19 months at increased risk of severe RSV are eligible for the shot in WA from this month.

Apr 11, 2024 | rnz.co.nz | Archana Koirala |Brendan J McMullan |Emma Best

By Archana Koirala, Brendan McMullan, Christopher Blyth, Emma Best and Fiona Russell* of Analysis - As we look towards the peak season for respiratory viruses, the announcement of new respiratory syncytial virus (RSV) immunisation programmes for children in a number of Australian states is welcome news. Last month Western Australia became the first Australian state or territory to announce a state government-funded immunisation program against RSV.

Apr 10, 2024 | theconversation.com | Archana Koirala |Brendan J McMullan |Emma Best |Fiona Russell

Archana Koirala has received institutional funding from the Australian Government Department of Health and Snow Foundation. Archana Koirala is a member of the Australasian Society of Infectious Diseases (ASID), Australia and New Zealand Paediatric Infectious Diseases Group and Chair of the Vaccine Special Interest Group within ASID. Brendan McMullan receives funding from the National Health and Medical Research Council.